Theragnostics Ltd.
🇬🇧United Kingdom
- Country
- 🇬🇧United Kingdom
- Ownership
- Subsidiary
- Established
- 2015-01-01
- Employees
- 1
- Market Cap
- -
- Website
- https://theragnostics.com
Clinical Trials
3
Active:1
Completed:1
Trial Phases
2 Phases
Phase 1:2
Phase 2:1
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (3 trials with phase data)• Click on a phase to view related trials
Phase 1
2 (66.7%)Phase 2
1 (33.3%)Phase 1 Open-label Study of 123I-ATT001 in Subjects with Relapsed Glioblastoma
- First Posted Date
- 2024-10-21
- Last Posted Date
- 2024-10-21
- Lead Sponsor
- Theragnostics Ltd
- Target Recruit Count
- 67
- Registration Number
- NCT06650605
- Locations
- 🇬🇧
University College London Hosptial, London, United Kingdom
🇬🇧University Hospital Southampton, Southampton, United Kingdom
68Ga-THP-PSMA PET/CT Imaging in High Risk Primary Prostate Cancer or Biochemical Recurrence of Prostate Cancer
- First Posted Date
- 2018-08-06
- Last Posted Date
- 2020-06-24
- Lead Sponsor
- Theragnostics Ltd
- Target Recruit Count
- 49
- Registration Number
- NCT03617588
- Locations
- 🇬🇧
St Bartholomew's Hospital (PIC), London, United Kingdom
🇬🇧Royal Free Hospital (PIC), London, United Kingdom
🇬🇧Guy's and St Thomas' Hospital (PIC), London, United Kingdom
News
No news found